Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?

To: johnsto1 who wrote (623)	9/22/2000 8:01:50 PM
From: Tom Hua	Read Replies (1) \| Respond to of 810

johnsto1, that's exactly right, there'll be no data from Phase III in 2 years. As you know from clinical trials, blind data will not be available nor can they be interpreted until the trials are done. And if you don't believe it, it's obious you haven't talked to the company yet. This is taken from a recent article, spin however you want. Bottom line is patients die anyway. ONYX-015 has to be injected directly into the tumour to work, meaning it is of no apparent use against tumours that are not easy to reach, or against tiny tumours that are not yet visible. The researchers said most of their patients eventually died of their cancer -- because other, untreated tumours in their body spread. regards, Tom